Latest Naloxone Stories
RICHMOND, Va., April 7, 2014 /PRNewswire/ -- Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to
First and only naloxone product specifically intended for emergency administration by family members or caregivers in settings where opioids may be present RICHMOND, Va., April 3, 2014 /PRNewswire/
There are important parallels between the early years of the HIV/AIDS epidemic and the current epidemic of opioid addiction - ones that could trigger a significant shift in opioid addiction prevention, diagnosis and treatment.
Ashfield Market Access to provide managed markets and trade support RALEIGH, N.C., March 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc.
Developers Continue to Focus Efforts on Formulation Improvements, According to Findings from Decision Resources Group BURLINGTON, Mass., March 17, 2014 /PRNewswire/ -- Decision Resources Group
PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials.
RALEIGH, N.C., March 5, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A.
The death of actor Philip Seymour Hoffman from a heroin overdose has generated discussion regarding medical treatment to prevent heroin deaths.
First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., Jan. 30, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc.
- A gift; a largess; a gratuity; a present; a dole.